Organigram Global Inc.

Organigram to Acquire Aurora and Establish a Global Cannabis Leader

Organigram agreed to acquire Aurora Cannabis for C$7.80 per share, valuing Aurora at approximately C$561 million on a fully diluted basis. The offer represents a 93% premium to Aurora's unaffected price and a 21% premium to Curaleaf's hostile bid, which Aurora's board unanimously rejected. Aurora shareholders can elect cash, 5.8626 Organigram shares, or a mix, subject to proration, and are expected to hold roughly 35% pro forma economic ownership of the combined company. The deal has unanimous board support from both companies, C$50 million in identified synergies, and a fully committed financing package including a C$187.5 million BAT private placement and up to $210 million in ATB credit facilities. Closing is expected in January 2027, subject to shareholder, court, and regulatory approvals including German foreign investment clearance.

•5d ago

Organigram Provides Update on Integration of Sanity Group and Unified Global Operating Model

Organigram completed the accelerated integration of Sanity Group GmbH and is moving to a unified global operating model, with global functions, operations, and innovation centralized across the enterprise. The company expects $8-10 million in annualized run-rate cost savings, with $5-6 million hitting fiscal 2027 against $2 million in one-time integration costs. Three brands are being discontinued and SKU assortment trimmed, concentrating investment behind core brands SHRED, BOXHOT, and Big Bag O' Buds to support gross margin improvement.

•24d ago

Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure

Organigram is accelerating the integration of its Sanity Group subsidiary under a unified global operating structure, appointing Finn Age Hänsel as President, Rest of World & CSO and Adrian Frenzel as Global COO to lead the combined platform. The company amended the Sanity acquisition agreement to fix the earnout at 85% of the original maximum, replacing performance metrics with a fixed consideration of €20 million in cash and approximately €76 million in shares. Sanity contributed over 35% of Organigram’s net revenue in the most recent quarter, totaling CAD$40 million, and has grown its quarterly revenue to €25.5 million.

•2mo ago

Organigram Reports Record Third Quarter Fiscal 2026 Results

Organigram reported record fiscal Q3 results with net revenue increasing 49% year-over-year to $105.8 million and Adjusted EBITDA rising 136% to $13.4 million. The growth was primarily driven by the Sanity Group acquisition, which contributed roughly C$40 million in net revenue and helped expand adjusted gross margins to 37%. While net income soared to $105.5 million due to non-cash fair value gains, free cash flow was a negative $3.9 million due to working capital investment; the company remains on track to exceed $350 million in annual revenue.

•2mo ago

Organigram Provides Business Update Highlighting Initial Sanity Performance and Canadian Market Share

Organigram reported that Sanity Group has maintained an approximate 10% market share in Germany since the April 15 acquisition, performing in line with revenue expectations. In Canada, the company held the #1 position in flower and vapes with 12.5% and 14.5% share respectively, while overall recreational market share stabilized sequentially with a 100 basis point improvement in June versus May. Management noted that recent regulatory changes in Germany regarding medical cannabis reimbursement are not expected to have a material impact as those sales represent only about 1% of Sanity's revenue.

•3mo ago